You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 8,263,554

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,263,554

Title:	Methods of using GLP-1 receptor agonists to treat pancreatitis
Abstract:	The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
Inventor(s):	Tatarkiewicz; Krystyna (San Diego, CA), Parkes; David G. (Del Mar, CA), Roy; Denis (Vista, CA), Gedulin; Bronislava (Del Mar, CA)
Assignee:	Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	13/155,211
Patent Claims:	1. A method for treating acute pancreatitis in a human in need thereof comprising administering to the human a therapeutically effective amount of exenatide to treat acute pancreatitis. 2. A method for treating pancreatitis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist to treat pancreatitis. 3. The method of claim 2, wherein the pancreatitis is acute pancreatitis. 4. The method of claim 3, wherein the acute pancreatitis is acute hemorrhagic pancreatitis. 5. The method of claim 3, wherein the acute pancreatitis is acute necrotizing pancreatitis. 6. The method of claim 3, wherein the acute pancreatitis is acute hemorrhagic-necrotizing pancreatitis. 7. The method of claim 2, wherein the GLP-1 receptor agonist is exenatide. 8. The method of claim 2, wherein the GLP-1 receptor agonist is a peptide having at least 75% sequence identity to exenatide. 9. The method of claim 2, wherein the GLP-1 receptor agonist is a peptide having at least 90% sequence identity to exenatide. 10. The method of claim 2, wherein the GLP-1 receptor agonist is lixisenatide. 11. The method of claim 2, wherein the GLP-1 receptor agonist is liraglutide. 12. The method of claim 2, wherein the GLP-1 receptor agonist is dulaglutide. 13. The method of claim 2, wherein the GLP-1 receptor agonist is albiglutide or taspoglutide. 14. The method of claim 2, wherein the GLP-1 receptor agonist is lixisenatide; CJC-1134; SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:46; SEQ ID NO:47; SEQ ID NO:48; SEQ ID NO:49; SEQ ID NO:50; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:53; SEQ ID NO:54; SEQ ID NO:55; SEQ ID NO:56; SEQ ID NO:57; SEQ ID NO:58 or SEQ ID NO:59. 15. The method of claim 2, wherein the GLP-1 receptor agonist is LY2428757; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; HXaa.sub.8EGTFTSDVSSYLEXaa.sub.22Xaa.sub.23AAKEFIXaa.sub.30WLXaa.sub.33Xa- a.sub.34GXaa.sub.36Xaa.sub.37 (SEQ ID NO: 25); wherein Xaa.sub.8 is A, V, or G; Xaa.sub.22 is G, K, or E; Xaa.sub.23 is Q or K; Xaa.sub.30 is A or E; Xaa.sub.33 is V or K; Xaa.sub.34 is K, N, or R; Xaa.sub.36 is R or G; and Xaa.sub.37 is G, H, P, or absent; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:43; SEQ ID NO:60; SEQ ID NO:61; SEQ ID NO:62; or SEQ ID NO:63. 16. The method of claim 1, wherein the acute pancreatitis is acute hemorrhagic pancreatitis. 17. The method of claim 1, wherein the acute pancreatitis is acute necrotizing pancreatitis. 18. The method of claim 1, wherein the acute pancreatitis is acute hemorrhagic-necrotizing pancreatitis.

Details for Patent 8,263,554

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014	⤷ Try a Trial	2030-06-09
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/18/2014	⤷ Try a Trial	2030-06-09
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/04/2020	⤷ Try a Trial	2030-06-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.